Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Retrospective study of transcriptomic profiling identifies Thai triple-negative breast cancer patients who may benefit from immune checkpoint and PARP inhibitors.
Suntiparpluacha M, Chanthercrob J, Sa-Nguanraksa D, Sitthikornpaiboon J, Chaiboonchoe A, Kueanjinda P, Jinawath N, Sampattavanich S. Suntiparpluacha M, et al. Among authors: sampattavanich s. PeerJ. 2023 Jun 12;11:e15350. doi: 10.7717/peerj.15350. eCollection 2023. PeerJ. 2023. PMID: 37334114 Free PMC article.
Dependency of Cholangiocarcinoma on Cyclin D-Dependent Kinase Activity.
Sittithumcharee G, Suppramote O, Vaeteewoottacharn K, Sirisuksakun C, Jamnongsong S, Laphanuwat P, Suntiparpluacha M, Matha A, Chusorn P, Buraphat P, Kakanaporn C, Charngkaew K, Silsirivanit A, Korphaisarn K, Limsrichamrern S, Tripatara P, Pairojkul C, Wongkham S, Sampattavanich S, Okada S, Jirawatnotai S. Sittithumcharee G, et al. Among authors: sampattavanich s. Hepatology. 2019 Nov;70(5):1614-1630. doi: 10.1002/hep.30704. Epub 2019 Jul 1. Hepatology. 2019. PMID: 31077409
Novel Analytical Platform For Robust Identification of Cell Migration Inhibitors.
Somchai P, Phongkitkarun K, Kueanjinda P, Jamnongsong S, Vaeteewoottacharn K, Luvira V, Okada S, Jirawatnotai S, Sampattavanich S. Somchai P, et al. Among authors: sampattavanich s. Sci Rep. 2020 Jan 22;10(1):931. doi: 10.1038/s41598-020-57806-0. Sci Rep. 2020. PMID: 31969633 Free PMC article.
The Acquired Vulnerability Caused by CDK4/6 Inhibition Promotes Drug Synergism Between Oxaliplatin and Palbociclib in Cholangiocarcinoma.
Suppramote O, Prasopporn S, Aroonpruksakul S, Ponvilawan B, Makjaroen J, Suntiparpluacha M, Korphaisarn K, Charngkaew K, Chanwat R, Pisitkun T, Okada S, Sampattavanich S, Jirawatnotai S. Suppramote O, et al. Among authors: sampattavanich s. Front Oncol. 2022 May 17;12:877194. doi: 10.3389/fonc.2022.877194. eCollection 2022. Front Oncol. 2022. PMID: 35664774 Free PMC article.
Comprehensive drug response profiling and pan-omic analysis identified therapeutic candidates and prognostic biomarkers for Asian cholangiocarcinoma.
Jamnongsong S, Kueanjinda P, Buraphat P, Sakornsakolpat P, Vaeteewoottacharn K, Okada S, Jirawatnotai S, Sampattavanich S. Jamnongsong S, et al. Among authors: sampattavanich s. iScience. 2022 Sep 23;25(10):105182. doi: 10.1016/j.isci.2022.105182. eCollection 2022 Oct 21. iScience. 2022. PMID: 36248745 Free PMC article.
Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma.
Prasopporn S, Suppramote O, Ponvilawan B, Jamyuang C, Chanthercrob J, Chaiboonchoe A, More-Krong P, Kongsri K, Suntiparpluacha M, Chanwat R, Korphaisarn K, Okada S, Sampattavanich S, Jirawatnotai S. Prasopporn S, et al. Among authors: sampattavanich s. Front Oncol. 2022 Nov 30;12:1021632. doi: 10.3389/fonc.2022.1021632. eCollection 2022. Front Oncol. 2022. PMID: 36531039 Free PMC article.
Corrigendum: Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma.
Prasopporn S, Suppramote O, Ponvilawan B, Jamyuang C, Chanthercrob J, Chaiboonchoe A, More-Krong P, Kongsri K, Suntiparpluacha M, Chanwat R, Korphaisarn K, Okada S, Sampattavanich S, Jirawatnotai S. Prasopporn S, et al. Among authors: sampattavanich s. Front Oncol. 2023 Jan 6;12:1124912. doi: 10.3389/fonc.2022.1124912. eCollection 2022. Front Oncol. 2023. PMID: 36686801 Free PMC article.
The KRAS-Mutant Consensus Molecular Subtype 3 Reveals an Immunosuppressive Tumor Microenvironment in Colorectal Cancer.
Tanjak P, Chaiboonchoe A, Suwatthanarak T, Acharayothin O, Thanormjit K, Chanthercrob J, Suwatthanarak T, Wannasuphaphol B, Chumchuen K, Suktitipat B, Sampattavanich S, Korphaisarn K, Pongpaibul A, Poungvarin N, Grove H, Riansuwan W, Trakarnsanga A, Methasate A, Pithukpakorn M, Chinswangwatanakul V. Tanjak P, et al. Among authors: sampattavanich s. Cancers (Basel). 2023 Feb 8;15(4):1098. doi: 10.3390/cancers15041098. Cancers (Basel). 2023. PMID: 36831441 Free PMC article.
26 results